USHEALTH Group has always stood out as the leading company in providing health care insurance to clients all over the world. The company could not have been successful without quality leadership. Tony McQuagge has been the firm’s CEO since 2010; he has delivered excellent services throughout his time. From his excellence Troy has been recognized as Chief Executive Officer of the year by One Planet Awards, he was the gold winner, and the price has built his reputation as well as the company. The awards recognize players in different sectors of the economy from all over the world and to receive any of the prizes a vigorous vetting process is conducted to ascertain that the person receiving the award deserves. Troy McQuagge was incredibly honored and it has shown the whole world that he is a great business leader and read full article.
Troy McQuagge joined the firm when its distribution channels were not very active; to ensure that the company succeeds Troy first rebuilt its distribution agency. It is from this ability to restructure the firm that Troy was named as the Enterprise President and CEO. Through Troy’s leadership, the company has been able to achieve great success and to compete with the largest health insurance firms around the globe. In his acceptance speech for the award, he said that the award was not his rather than the company’s at large. USHEALTH Health Group has gained popularity since Troy got the award and he is laying strategies to open more branches across the world.
The health care sector has faced a lot of challenges and Troy’s aim is to make USHEALTH group the most affordable firm offering clients health insurance. The company serves business people and employed individuals. The company’s head offices are in Texas, with a dedicated team of employees the company has been able to offer customer friendly services.
Troy McQuagge studied at the prestigious University of Central Florida where he graduated with a degree in Legal Studies. Troy has worked in the health insurance industry for many years and the experience he acquired has been very paramount for USHEALTH Group. His first company to work for was Allstate Insurance in 1983 and 1995 he moved Health Market and follow Troy of Twitter.
Jeanmarie Guenot is a business executive in the pharmaceutical and biotechnology industry. Guenot currently serves as the President and CEO of Amphivena Therapeutics in San Francisco, CA. Guenot has vast knowledge and over 20 years of experience in dealing with cardiovascular diseases neurology, ophthalmic and autoimmune diseases, and oncology. Jeanmarie Guenot graduated from the University of California, San Francisco in 1993 with a Ph.D. and studied her MBA at the University of Pennsylvania, Wharton School. Her extensive knowledge in medicinal and physical knowledge with specialties in quantum mechanical and semi-empirical methods have seen her hold various executive positions in various companies.
LinkedIn shows us that Guenot has previously worked in different private and public companies in the pharmaceuticals, venture capitals, and business development sectors. After completion of her Ph.D. degree, Jeanmarie Guenot started her career in science at Hoffman- La Roche in 1993 as the principal scientist in Preclinical R&D. She later engaged in a business career at the Atlas Venture. At the company, she was in charge of the venture capital investment management and helped in building life science companies. Guenot was the vice president of PDL BioPharma and Managing Partner at Guenot LLC. In 2009, she founded SKS Ocular LLC, a biopharmaceutical company in San Diego, CA.
As the CEO of Amphivena Therapeutics, Guenot has led the company in developing bi-functional antibody therapies in the treatment of the hematological malignancies. The company has developed drugs such as the CD3 and the AMV-364 for the treatment of myeloid leukemia. The pharmaceutical company aims at developing drugs that restore the cellular balance in patients facing life-threatening diseases.
Significant Accomplishments at PDL BioPharma
Guenot played an important part at PDL BioPharma for the five years that she was the vice president in Business Development. Her role in the company included alliance management of profit and losses, licensing, as well as mergers and acquisitions. Guenot also licensed Ophthotech for the ophthalmic indication on the oncology drug. She contributed greatly to the co-development and co-commercialization collaboration between PDL and Biogen Idec. The $800M transaction involved three Phase 2 Cancer Patients and autoimmune drug candidates.